{{위키데이터 속성 추적}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 464367349
| IUPAC_name = 4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol
| image = Dihydrocodeine skeletal.svg
| image2 = Dihydrocodeine3DanJ.gif

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|dihydrocodeine}}
| pregnancy_US = 
| legal_AU = S3
| legal_AU_comment = {{longitem|(S3) (S4) (S8) depending on dose and other constituents}}
| legal_CA = Schedule I
| legal_DE = Rx-only/Anlage III
| legal_UK = Class B
| legal_US = Schedule II / Schedule III in Combination.
| legal_status =  
| routes_of_administration = {{hlist |[[Oral administration|oral]] |[[Subcutaneous administration|subcutaneous]] |[[Intramuscular injection|intramuscular]] |[[Suppository|rectal]] |possibly&nbsp;[[Sublingual administration|sublingual]]{{\}}[[Buccal administration|buccal]]}}
<!--Pharmacokinetic data-->
| bioavailability = 20%<ref name="EurJClinPharmacol1983-Rowell">{{저널 인용|vauthors=Rowell F, Seymour R, Rawlins M |title=Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites |journal=Eur J Clin Pharmacol |volume=25 |issue=3 |pages=419–24 |year=1983 |pmid=6628531 |doi=10.1007/BF01037958|s2cid=29370394 }}</ref>
| metabolism = {{longitem|Mainly [[liver|hepatic]], through [[CYP3A4]] and [[CYP2D6]]}}
| elimination_half-life = 4 hours<ref name="EurJClinPharmacol1983-Rowell"/>
| excretion =  
<!--Identifiers-->
| IUPHAR_ligand = 7594
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 125-28-0
| ATC_prefix = N02
| ATC_suffix = AA08
| PubChem = 5284543
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01551
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4447600
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = N9I9HDB855
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07831
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1595
<!--Chemical data-->
| C=18 | H=23 | N=1 | O=3
| smiles = O[C@@H]1[C@@H]2OC3=C(OC)C=CC4=C3[C@@]2([C@H]5CC1)CCN(C)[C@@H]5C4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RBOXVHNMENFORY-DNJOTXNNSA-N
| synonyms = 6α-Hydrocodol<ref name="FFFLM2007">{{서적 인용| vauthors = Karch SB |title=Pharmacokinetics and Pharmacodynamics of Abused Drugs|url=https://books.google.com/books?id=9fwUQvF4r-cC&pg=PA56|date=9 October 2007|publisher=CRC Press|isbn=978-1-4200-5460-6|pages=56–}}</ref>
| dependency_liability=Moderate-high|addiction_liability=Moderate-high
}}

'''디히드로코데인''' 또는 '''다이하이드로코데인'''({{llang|en|dihydrocodeine}})은 단독 또는 [[파라세타몰]]([[아세트아미노펜]]) ([[코디드라몰]]에서와 같이) 또는 [[아스피린]]과 혼합하여 통증 또는 중증 [[호흡곤란]] 또는 [[감기약|진해제]]로 처방되는 반[[화학 합성|합성]] [[아편유사제|아편유사]] [[진통제]]이다. 다이하이드로코데인은 1908년에 독일에서 개발되어 1911년에 최초로 시판되었다.<ref>{{서적 인용|url=https://books.google.com/books?id=qoyYobgX0uwC|title=Encyclopedia of Psychopharmacology| vauthors = Stolerman I |date=2010-07-31|publisher=Springer Science & Business Media|isbn=9783540686989|language=en}}</ref>

== 같이 보기 ==
* [[코데인]]

== 각주 ==
{{각주}}

[[분류:사이클로헥산올]]
[[분류:독일의 발명품]]
[[분류:뮤 오피오이드 수용체 작용제]]
[[분류:카테콜 에터]]
[[분류:반합성 오피오이드]]
[[분류:4,5-에폭시모르피난]]